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In differentiated smooth muscle cells (SMC) the regulation of SMC marker genes (e.g. α-smooth muscle actin) is mainly conducted by the
serum response factor (SRF) and accessory co-factors like myocardin. A number of SMC markers are also expressed in activated hepatic stellate
cells which are the main cellular effectors in liver fibrogenesis. In the present study we found that during cellular activation and transdifferentiation
the SRF transcription factor is up-regulated by transforming growth factor-β, accumulated in the nucleus, and exhibited increased DNA-binding
activity. These observations were accompanied by a forced expression of the SRF co-activator myocardin. Specific targeting of SRF by small
interference RNA resulted in diminished contents of α-smooth muscle actin. Therefore, we conclude that hepatic stellate cells retain differentiation
capacity to evolve characteristics that are typical for cells of the cardiac and smooth muscle lineages.
© 2007 Elsevier B.V. All rights reserved.Keywords: Serum response factor; Hepatic stellate cell; Transdifferentiation; Smooth muscle cell; Transforming growth factor-β; Myocardin; Gene regulation;
siRNA; α-Smooth muscle actin; Liver fibrogenesis1. Introduction
The serum response factor (SRF) is ubiquitously expressed
and a founding member of the MADS-box containing tran-
scription factor family. It is predominantly localised in the nu-
cleus and binds to a specific sequence in the promoters of diverse
target genes, called CArG-box. Thus, it was found that SRF is
mainly involved in differentiation of cardiac, skeletal, or smooth
muscle cells (SMC) by regulation of genes controlling cell
growth, cytoskeletal organisation, cell contractility, and cellu-
lar motility [1]. Comprehensive research in vascular SMC and
myofibroblasts revealed the relevance of SRF in regulating
marker genes of cellular differentiation and of the contractile
apparatus, e.g. α-smooth muscle actin (α-SMA), SM22α (trans-
gelin), or smooth muscle-myosin heavy chain (SM-MHC) [2].Abbreviations: α-SMA, α-smooth muscle actin; ALK5, activin receptor-like
kinase 5; DMEM, Dulbecco's modified Eagle medium; EMSA, electrophoretic
mobility shift assay; FCS, fetal calf serum; HSC, hepatic stellate cell(s); IgG,
immunoglobulin G; MFB, myofibroblast-like cell(s); siRNA, small interference
RNA; SMC, smooth muscle cell(s); SRE, serum response element; SRF, serum
response factor; STR, soluble TGF-b type II receptor; TGF-b, transforming
growth factor-β
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doi:10.1016/j.bbadis.2007.10.006Expression of SRF is inducible by the transforming growth
factor-β1 (TGF-β1) [3] and its transcriptional activity depends
on phosphorylation of distinct serine or threonine residues [4–7].
It has been demonstrated that TGF-β-induced differentiation of
embryotic 10T1/2 mesenchymal cells into a SMC phenotype
was necessarily mediated by a strong up-regulation of SRF ac-
companied by enhanced DNA-binding activity [8]. The SRF-
mediated control of myogenic genes is influenced by TGF-β-
dependent RhoA/Rho kinase pathway and cytoplasmic G-actin
polymerisation [9,10]. Contrarily, it was shown that the platelet-
derived growth factor-BB (PDGF-BB) suppressed α-SMA
expression by cellular redistribution of SRF out of the nucleus
in rat aortic vascular SMC [11]. Since SRF binds to several
promoters and controls disparate programs of gene expression,
the specificity in activation requires different accessory co-
activators, whereas SRF-mediated regulation of SMC differentia-
tion marker genes is essentially supported by myocardin [12,13].
Chronic liver injury induces activation of hepatic stellate cells
(HSC) that transit from a quiescent, fat-storing phenotype into a
proliferative, extracellular matrix-producingmyofibroblastic cell
type (MFB) [14]. This differentiation process is accompanied
amongst others by up-regulation of SMC marker genes [15,16]
and enhanced susceptibility for TGF-β, the main profibrogenic
cytokine during liver fibrogenesis [14]. To date, the molecular
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expression in activated HSC are only partially known. It has been
demonstrated that antagonising of TGF-β signalling by a sol-
uble TGF-β type II receptor (STR), antisense RNA or transient
over-expression of the TGF-β antagonist Smad7 influences α-
SMA expression and cytoskeletal organisation [17–19]. Block-
ing of the p38 mitogen activated protein kinase (MAPK) had a
repressive impact on α-SMA expression by influencing theFig. 1. Expression and cellular localisation of SRF in activated HSC. (A) Increased S
blot of cell lysates (60 μg each) taken from HSC or MFB cultured for indicated time
analysis of SRF expression in activated HSC and MFB. The contents of SRF and w
densiometry and the SRF content was normalised against the whole protein data in eac
(C) SRF accumulates in the nucleus of activated HSC but is found to a lesser exte
activated HSC at day 2 or day 7 of culturing and in 4 days cultured MFB are show
overlays of SRF (green) and nuclear stains (red) resulting in a yellow dyeing that is mo
shown in bright field. Negative controls (right panel) showed only nuclear staining. B
performed in triplicate with cells taken from three independent HSC preparations.expression of the transcription factor myocyte enhancer factor 2
(MEF2) [20]. The suppression of RhoA activity in trichostatinA-
treated HSC reduced the content of α-SMA and impaired the
formation of actin filament formation that was also observed
when the cells were treated with the Rho kinase inhibitor Y-
27632 [21,22]. However, the expression and functional role of
SRF in liver is only sparely investigated. A very recent paper
addressed the relevance of SRF for liver regeneration after partialRF and α-SMA expression during transdifferentiation. A representative Western
points is shown. Ponceau S staining served as loading control. (B) Densiometric
hole protein in Ponceau S stain from (A) were semi-quantitatively measured by
h sample. The determined value for SRF at day 1 of cultivation was set as 100%.
nt in nuclei of MFB. Representative immunofluorescence stainings of SRF in
n. Nuclei were counterstained with propidium iodide. The left panel represents
st prominent in HSC cultured for 7 days. In the middle panel, the same fields are
oth, the Western blots and immunofluorescent cytochemistry experiments were
Fig. 2. Expression of myocardin during transdifferentiation. (A) Myocardin
contents are increased in activated HSC. Total proteins extracts from HSC at
indicated time points were isolated and analysed (80 μg each) byWestern blot. As
shown in this representative experiment, the expression of myocardin is elevated
during HSC transdifferentiation peaking at day 7 of culturing and followed by a
slight down-regulation in MFB cultured for 4 days. Ponceau S staining was used
as loading control. The detection of myocardin was performed in triplicate with
cells taken from three independent HSC preparations each. (B) Densiometric
analysis of myocardin expression in activated HSC and MFB. The individual
myocardin contents of the 3 independent Western blot analyses with cell lysates
taken from 3 individual HSC preparations were normalised against the respective
amounts of total protein in each sample as depicted by Ponceau S staining. In this
analysis, the determined value for myocardin at day 1 of cultivation in the 3
individual cell preparations was set as 100% and the calculated averages with the
respective standard deviations are shown.
1252 J. Herrmann et al. / Biochimica et Biophysica Acta 1772 (2007) 1250–1257hepatectomy, which was delayed in mice conditionally deleted
for SRF in hepatocytes [23].
The aim of the present study was to analyse the expression of
SRF and its function for SMC marker gene activity in activated
HSC and transdifferentiated MFB. We found that (i) the ex-
pression and activity of SRF increased during cellular activation,
(ii) concomitantly the expression of the accessory SRF co-factor
myocardin elevates, (iii) SRF expression is controlled by TGF-
β1, merely partial via the ALK5 signalling pathway, and (iv)
SRF is a critical mediator in the control of SMC marker gene
expression in HSC. These results support previous studies
demonstrating that SRF essentially contributes to the emergence
of myofibroblasts during injury of lung and oesophagus [24,25].
Moreover, these findings underpin the notion that HSC imply
high cellular plasticity allowing them to adopt of a SMC
phenotype.
2. Materials and methods
2.1. Isolation and culture of HSC
HSC were isolated from male Sprague–Dawley rats by the pronase–
collagenase method, followed by centrifugation in a Nycodenz gradient as
described [26]. Cells were seeded in Dulbecco's modified Eagle medium
(DMEM) (Bio Whittaker Europe, Verviers, Belgium) supplemented with 10%
(v/v) fetal calf serum (FCS) (Hyclone, Perbio, Bonn, Germany), and 4mM L-
glutamine (PAA Laboratories, Linz, Austria), 100IU/ml penicillin and 100μg/ml
streptomycin (PAA Laboratories). MFB were prepared from HSC by
trypsinization at day 7 of primary culture. For induction, freshly isolated HSC
were cultured 1day in medium containing 10% FCS, starved for 24h in medium
containing 0.2% FCS, then preincubated for 1h in serum free medium and
subsequently stimulated with 1ng/ml recombinant human TGF-β1 (R&D Sys-
tems, Wiesbaden, Germany) for additional 4h or left untreated. The experiments
for antagonizing TGF-β signalling were performed with 1μg/ml soluble TGF-β
type II receptor (STR) or 5μMALK5 inhibitor SB-431542 (Sigma, Taufkirchen,
Germany) as described [27]. Specific down-regulation of SRF in rat HSC was
achieved by addition of 10nM siRNA (Rn_LOC301242_2_HP) and the
HyPerFect transfection reagent (Qiagen, Hilden, Germany) 1day after seeding.
The study as presented was approved by the local committee for care and use of
laboratory animals, and was performed according to strict governmental and
international guidelines on animal experimentation.
2.2. Adenoviral infection of HSC
Primary HSC were seeded in 6-well dishes at 3 × 105 cells/well and infected
at day 1 of culturing with 2 × 108pfu adenoviral constructs Ad5-CMV-GFP,
Ad5-SM22α-GFP, or Ad5-TIMP-1-GFP as described previously [16]. The
expression of GFP was monitored by fluorescence microscopy.
2.3. SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and
immunoblotting
Cell lysates were quantified byBradford assay and 60 to 80μg total protein (as
indicated in the respective figure legends) were resolved on a 4–12% (w/v) Bis–
Tris gel (Invitrogen, Carlsbad, CA) in SDS-PAGE under reducing conditions in
MOPS buffer and proteins were electroblotted onto a Protran membrane
(Schleicher & Schuell, Dassel, Germany) according to standard procedures. After
blocking, the membranes were incubated with primary antibodies against SRF
(HM1350; Hypromatrix, Worcester, MA), myocardin (sc-21559; Santa Cruz
Biotech., Santa Cruz, CA), SM22α (ab10135; Abcam, Cambridge, UK), or α-
SMA (CBL171; Cymbus Biotechnology Ltd., Chandlers Ford, UK) in 1:1000
dilutions. The formed immunocomplexes were subsequently detected with hor-
seradish peroxidase-conjugated anti-mouse or anti-rabbit IgG in a 1:5000
dilution. The detection of the ribosomal protein S6 (54D2) (#2317; Cell Signaling
Technology, Beverly,MA)was used as loading control. In addition, equal loadingof the individual lanes was further confirmed by densiometric analysis of Ponceau
S staining. Densiometric analysis was done using the LumiAnalyst 3.0 software
(Roche Diagnostics, Mannheim, Germany).
2.4. Electrophoretic mobility shift assay (EMSA)
Whole cell lysates (15μg) were incubated with 35fmol 32P-labeled, double-
stranded consensus SRE probes (sc-2523; Santa Cruz) in binding buffer [10mM
Tris (pH 7.5), 50mMNaCl, 1mMMgCl2, 0.5mM EDTA, 0.5mMDTT, 4% (v/v)
glycerol, 1:500 Protease-Inhibitor Cocktail (Sigma), 1:100 Phosphatase-Inhi-
bitor Cocktail 2 (Sigma)] and in the presence of 1μg poly[d(I–C)] (Roche
Diagnostics). Competitor oligonucleotides [consensus- or mutant-SRE (sc-2524;
Santa Cruz)] were included in a 40-fold molar excess. Supershift analyses were
performed with 200ng anti-SRF antibody (sc-335; Santa Cruz) or normal rabbit
IgG (sc-2027; Santa Cruz). Samples were resolved on 6% DNA retardation gels
Fig. 3. DNA-binding activity of SRF and SM22α reporter gene expression during transdifferentiation. (A) Enhanced DNA binding of SRF in activated HSC is
diminished in MFB. In the left panel, the DNA-binding capacity of SRF during HSC transdifferentiation was analysed by EMSA. Therefore, whole cell lysates were
taken from cultured HSC/MFB at indicated time points and incubated with a radiolabeled oligonucleotide containing the SRE consensus sequence. In the right panel, a
40-fold excess of unlabeled SRE consensus or a mutant-SRE served as a control for specificity. In addition, a supershift was induced with an antibody directed against
SRF. In this analysis, a control IgG served as a further control. The extracts used in this EMSAwere taken from HSC that were cultured for 7 days. The presented
EMSAs reveal representative data of three independent experiments. (B) SRF target gene expression correlates with its DNA-binding activity. One day cultured HSC
were infected with the adenoviral constructs Ad5-CMV-GFP (upper panel), Ad5-SM22α-GFP (middle panel), or Ad5-TIMP-1-GFP (lower panel), respectively. The
expression of the GFP reporter gene was visualized at indicated time points by fluorescence microscopy. Respective bright field views are depicted in parallel.
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Fig. 4. SRF expression is TGF-β-dependent in activated HSC. (A) Culture-
activated HSC were treated with 1 ng/ml TGF-β1 under starvation conditions as
described in Materials and methods. Western blot analysis (60 μg total protein/
lane) revealed that the SRF content increased rapidly in cells that were treated
with TGF-β1 for 4 h. Detection of the ribosomal S6 protein served as loading
control. (B) Freshly isolated HSCwere seeded in the presence of 1 μg/ml soluble
TGF-β type II receptor (STR). The cells were harvested at day 7 of culturing and
lysates taken from treated or untreated cells (60 μg each) were analysed for SRF
expression by Western blotting. The result as shown in the representative
immunoblot supports the observation presented in A that TGF-β is mainly
involved in SRF up-regulation during HSC transdifferentiation. The ribosomal
S6 protein served as an internal loading control. (C) Primary rat HSC were
incubated at day 1 of culturing with 5 μM ALK5 inhibitor SB-431542. Cell
extracts (60 μg each) were prepared at indicated time points and SRF expression
was detected by Western blot. Inhibition of the classic TGF-β signalling path-
way via Smad2/3 resulted in an only marginal down-regulation of SRF that was
observable in HSC that were cultured for 7 days. Detection of the ribosomal S6
protein served as loading control. All presented Western blot results are re-
presentative results of 3 independent experiments.
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that were subsequently dried under vacuum and exposed to Kodak X-OMATAR
films at − 80°C using intensifying screens.
2.5. Immunofluorescent cytochemistry
Approximately 3 × 105 freshly isolated rat HSC were seeded on coverslips
mounted in 6-well dishes. Two- or 7-day cultivated HSC as well asMFB cultured
for 4days were fixed in paraformaldehyde [4% in phosphate buffered saline
(PBS) pH 7.4], permeabilized on ice in 0.1% sodium citrate containing 0.1%
TritonX-100, and blocked against endogenous biotin in Biotin BlockingReagent
(X0590; DAKO, Hamburg, Germany) followed by unspecific blocking in PBS
(pH 7.4) supplementedwith 50%FCS and 0.5% bovine serum albumin. The cells
were then incubated with 10μg/ml anti-SRF and subsequently with a secondary
biotinylated swine anti-rabbit IgG (E0353; DAKO). Negative controls were
treated with the secondary antibody as described [28]. The immunocomplexes
were visualized by addition of FITC-labeled streptavidin (F0422; DAKO) in
laser-scanning microscopy (LEICA DM LB 100W; Leica Microsystems,
Wetzlar, Germany). Nuclei were counterstained with propidium iodide.
2.6. Statistical analysis
Results are presented as the mean of 3 independent experiments (± SD).
Statistical analysis was performed with a Student's t-test and differences were
considered as significant (⁎) at p b 0.01.
3. Results and discussion
3.1. SRF and myocardin are expressed in activated HSC
Wecomparatively analysed the expression of SRF andα-SMA
in primary HSC undergoing differentiation at different culture
days by Western blot (Fig. 1A). The content of both proteins
gradually increased during conversion fromquiescent to activated
HSC and at last fully differentiated MFB. We observed that SRF
was already present at low levels inHSC cultured for 1 and 2days,
while it increased rapidly at day 3 of cultivation resulting in a
doubling of SRF contents and followed by a further increase in
MFB (Fig. 1B). In contrast to the kinetics of SRF expression, the
amounts of α-SMA climaxed at day 2 of culturing reflecting the
transcriptional potency of SRF (Fig. 1A). Next we determined the
cellular localisation of SRF by immunocytochemistry revealing
that the transcription factor was already present in HSC cultured
for 2days and accumulated in the nuclei ofHSC thatwere cultured
for 7days (Fig. 1C). Interestingly, the amount of nuclear SRF was
diminished in MFB. Because SRF-mediated transcriptional
regulation of SMC marker genes is further dependent on specific
co-factors, we next analysed the expression of the accessory SRF
co-activator myocardin in lysates taken from culture-activated
HSC and MFB (Fig. 2A). Myocardin was initially up-regulated
early during cellular activation and peaked in 7days cultured
HSC. However, we found a slight decrease in myocardin ex-
pression in MFB (Fig. 2A and B). Interestingly, another SRF co-
factor, the LIM domain protein CRP2 that was shown to be a
potent SMC marker gene co-activator [29], exhibits a similar
expression pattern in activated HSC [30]. The simultaneous
activation of these genes previously shown to be SMC marker
genes suggests that the differentiation fromHSC toMFB is a well
orchestrated process in which HSC might acquire some char-
acteristics of SMC resulting in the expression of typical cyto-
skeletal compounds.3.2. SRF DNA-binding activity is enhanced in activated HSC
To prove if the expressed SRF is functionally active in HSC,
we performed EMSAs using the consensus CArG-box binding
motif (Fig. 3A). We found that the fraction of formed complexes
was highest at day 5 of culturing which was in agreement with
the result of the Western blot showing that SRF was highly
expressed at this time point. Contrarily, we observed a strong
reduction of DNA-binding capacity in fully differentiated MFB.
To analyse if the lowered SRF DNA binding caused changes in
target gene expression, we performed a reporter gene assay in
which HSC at day 1 were infected with the adenoviral constructs
Ad5-CMV-GFP, Ad5-SM22α-GFP, or Ad5-TIMP-1-GFP. The
expression of GFP driven by the constitutive active CMV pro-
moter was already detectable 1day after infection, increased at
later time points and stayed at high level in MFB (Fig. 3B). In
contrast, GFP expression regulated by a SM22α promoter frag-
ment harbouring CArG-boxes was hardly detectable 1day after
Fig. 5. SMC marker gene expression in activated HSC is influenced by SRF.
Primary HSC were transfected with siRNA directed against SRF (siSRF) or a
scrambled control siRNA at day 1 of culturing. Two days after transfection the
cells were harvested and protein expression levels were detected by Western
blotting (60 μg total protein/lane). (A) A representative Western blot analysis of
SRF, α-SMA and SM22α contents in whole cell lysates taken from HSC treated
with siRNA. SRF was markedly reduced, while the protein contents of the SMC
markers α-SMA or SM22α were decreased at lower levels. Detection of the
ribosomal S6 protein served as loading control. (B) Densiometric analyses of
SRF, α-SMA, and SM22α contents were performed with Western blot results
taken from three independent experiments. Data were normalised against S6
protein contents and statistical relevance was determined by the Student's t-test
(⁎ = pb0.01).
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typic transition to MFB indicating that the transcriptional ac-
tivity of SRF was reduced at later stages of differentiation. The
TIMP-1 promoter fragment without any SRF binding element
directed very weak expression of GFP that was hardly detectable
in HSC at day 5 of culturing. However, comparable to the ex-
pression obtained with the CMV promoter this expression level
stayed constant in MFB.
The discrepancy between total SRF protein content and
transcriptional activity in MFB might be the result of a partial
redistribution of SRF from the nucleus into the cytoplasm. In
line with this hypothesis, we demonstrated that nuclei of MFB
contained less SRF compared to HSC that were cultured for
7days (cf. Fig. 1C). Such an extra-nuclear redistribution of SRF
was previously shown in serum-deprived tracheal myocytes in
which the SRF transcriptional activity is regulated through
reversible translocation between cytoplasm and nucleus [31].
3.3. The increase of SRF protein in activated HSC is
TGF-β-dependent
TGF-β is the most prominent profibrogenic factor for HSC
activation and liver fibrogenesis and a powerful inducer of SMC
marker gene expression. Therefore, we tested if the expression of
SRF in HSC is influenced by this cytokine. Treatment of HSC
with TGF-β1 under starvation conditions resulted in a strong up-
regulation of SRF (Fig. 4A). In an opposing experimental ap-
proach the sequestering of active TGF-β by a soluble TGF-β
receptor type II (STR) led to a distinct reduction of SRF (Fig. 4B).
Blockade of the Smad2/Smad3 signalling pathway by the TGF-β
type I receptor ALK5 inhibitor SB-431542 had onlyminor effects
on SRF expression levels during HSC transdifferentiation
suggesting that this pathwaymight have only accessory relevance
in TGF-βmediated regulation of the srf gene (Fig. 4C). Likewise,
previous studies have shown that SRF expression in 10T1/2 cells
and canine tracheal SMC is influenced by TGF-β1 [3,32] but the
responsible intracellular mediators are still unknown. Our results
indicate that the classical TGF-β signalling cascade that is
mediated by Smad proteins [33] might play an only ancillary role
in the regulation of SRF expression in HSC. In general, SRF-
dependent SMC marker gene activation might be principally
regulated by two other mechanisms, (i) the transcriptional up-
regulation of SRF and (ii) the increase/decrease of SRF activity
by reversible shuttling between cytoplasm and nucleus that is
mediated by the RhoA/Rho kinase pathway [34]. The latter
mechanism might also contribute to SRF activity in activated
HSC because the selective GTPase Rho/Rho-associated kinase
inhibitor Y-27632 was shown to attenuate α-SMA expression
and contractility in HSC [22,35]. Previous reports have revealed
that MFB are insensitive towards the activity of TGF-β1 [36].
Possibly this insensitivity might be a reasonable explanationwhy
the overall SRF activity is decreased in MFB, while the SRF
protein contents remained constant (see above). It is also known
that the interaction of SRF and Smad3 is important for the
regulation of SM22α gene expression in TGF-β-stimulated
10T1/2 cells [3]. Likewise, this cooperative effect was inhibited
by over-expression of the Smad3-antagonist Smad7 in caninetracheal SMC [32]. Another study described that the TGF-β-
induced differentiation of the neural crest stem cell line Monc-1
into a SMC-like phenotype was attributed by a modulation of
Smad signalling by theRhoA/Rho kinase pathway [37]. All these
findings indicate that the classical TGF-β signalling pathway via
activation of Smad2 and Smad3 is potentially able to directly
affect SRF activity in other cellular systems.
3.4. SRF directs SMC marker gene expression in activated HSC
Next, we examined the influence of SRF for the regulation of
SMC marker genes in activated HSC. Therefore, we transfected
HSC at day 1 in primary culture with siRNA directed against
SRF mRNA and analysed the expression of SRF, α-SMA, and
SM22α after a further 2-day culture period. The analysis of 3
independent experiments revealed that the application of the
siRNA (i.e. siSRF) decreased the SRF content significantly (up
1256 J. Herrmann et al. / Biochimica et Biophysica Acta 1772 (2007) 1250–1257to averaged 74%) and subsequently the expression of α-SMA
without any significance as a result of a higher inter-expe-
rimental variance, while the SM22α expression remained un-
affected (Fig. 5A and B). We were not able to further increase
the expression of SRF by higher amounts of siSRF or other
siRNAs targeting endogenous SRF mRNA (data not shown).
The suppression of α-SMA expression demonstrated that SRF
indeed possesses a regulatory function in control of this SMC
marker gene in activated HSC. However, we were not able to
induce a relevant reduction of SM22α expression by the siSRF.
Possibly, the down-regulation achieved by the siRNA targeting
SRF expression was not sufficient to affect SM22α expression
or alternatively, the regulation of the α-SMA gene is more
reliant on SRF in HSC.
In conclusion, we have shown for the first time that SRF and
myocardin, which are essential regulators of SMC differentia-
tion, become expressed during the transition of quiescent HSC
into proliferative, fibrogenic, and contractile MFB. The poten-
tial of HSC to differentiate into SMC of the endothelial lineage
was recently suggested for HSC carrying the CD133 progenitor
cell marker [38] indicating the high degree of plasticity of this
cells. However, the data presented in this study imply that this
characteristic is a common feature of all HSC.
Future experiments investigating the activity and fine tuning
of the transcriptional machinery containing SRF, myocardin,
and other SRF accessory co-factors (e.g. CRP2) might lead to
fundamental insights in understanding the biology behind cel-
lular differentiation from HSC into its fibrotic counterpart (i.e.
MFB).
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